Effect of 13-valent pneumococcal conjugate vaccine on admissions to hospital 2 years after its introduction in the USA: a time series analysis -

Effect of 13-valent pneumococcal conjugate vaccine on admissions to hospital 2 years after its introduction in the USA: a time series analysis
Information type: Other primary research
Source: The Lancet Respiratory Medicine
Specialities: Vaccination
Summary
This research found that introduction of the 13-valent pneumococcal conjugate vaccine (PCV13; replaced PC7) in the US reduced residual invasive and non-invasive pneumococcal hospital admissions in children <5 years, as well as in some adult age groups, after only 2 years.
UKMi comment
The 13-valent pneumococcal conjugate vaccine (PCV13) replaced the seven-valent vaccine in the UK in 2010. It is recommended for infants from two months of age as part of the routine childhood immunisation schedule.
Related links: Comment Green book chapter 25 (pneumococcal)